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The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2.
Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage
and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late
administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of
CS in the early stage of the inflammatory phase resulted in favorable outcomes. Noteworthy, some inhaled
CS inhibited in vitro the viral replication of SARS-CoV-2. We aimed to define the place in therapy for CS
in COVID-19 infection describing the features of patients who may benefit from their administration.
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In January 2020, SARS-CoV-2 was isolated in Wuhan, China, and spread all over the country and subsequently
worldwide, infecting over 16,000.000 people, including >600,000 deaths worldwide (ECDC, 29 July 2020). The
clinical manifestations of COVID-19 range from mild symptoms to severe illness with bilateral pneumonia leading
to acute respiratory distress syndrome (ARDS) and multiple organ failure [1]. So far, there is a lack of data about
efficient treatment strategies for SARS-CoV-2 infection, and management is largely supportive.
Patients presenting with severe manifestations related to COVID-19 were reported to have increased plasma
concentrations of chemoattractant molecules and pro-inflammatory cytokines, including IL-10, IL-6, IL-1 and
TNF-α [2]. The innate and adaptive immune response largely contributes to the development of a ‘cytokine storm’,
playing a pivotal role throughout the development and progression of ARDS. In agreement with this, patients
with severe COVID-19 presented high levels of d-dimer, serum ferritin, IL-6 and C-reactive protein [2]. Treatment
strategies are focused on antivirals and immunomodulating agents differently combined.
Corticosteroids (CS), because of their anti-inflammatory properties, have been widely used among patients with
SARS-CoV and MERS-CoV with contrasting results [3–8]. However, most of the data came from observational
studies where CS were used in different doses. Furthermore, also the timing of CS administration may be crucial
for the efficacy of CS treatment. In fact, some patients received CS very early after diagnosis, others received CS as
a ‘rescue-therapy’ when other interventions failed [4,5,9,10].
Several studies reporting increased mortality following CS administration were carried out in intensive care unit
setting, usually in patients severely compromised or with pre-existing underlying comorbidities [4,5,9]. Based on
available data on steroids for the treatment of SARS and MERS-infected patients, early evidence was against the
use of CS and only weak recommendation based on low-quality evidence supported the use of CS for patients with
COVID-19 [11–13].
Systemic CS in COVID-19
The pathogenesis of SARS-CoV-2 infection has been proposed to occur during three phases. Following inoculation,
SARS-CoV-2 can rapidly spread and replicate within the epithelial cells of the respiratory tract or small intestine
causing mild and nonspecific symptoms (first phase). In the second phase, SARS-CoV-2 infection spreads to the
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Table 1. Proposed criteria to introduce systemic corticosteroids in the treatment of SARS-CoV-2 infection.
O2 supply requirement and ≥1 of the following criteria:
• Patient has dyspnea at rest or during minimal activity (sitting up in bed, standing, talking)
• Breathing rate 30 bpm
• PaO2 60 mmHg in ambient air at admission or worsening hypoxemia during hospitalization
• Persistent fever (body temperature 38◦C)
• Radiographic progression of lung opacities
• CRP mg/l 100
• Ferritin μg/l 1000
BPM: Beats per minute; CRP: C-reactive protein; O2: Oxygen; PaO2: Partial pressure of oxygen.
lungs resulting in pneumonia characterized by bilateral pulmonary infiltrates on chest imaging and worsening of
clinical symptoms with fever, cough, and in some cases, hypoxia. A little subgroup of patients with COVID-19
related pneumonia develops massive systemic inflammation, due to the upregulation of several pro-inflammatory
and procoagulant cytokines leading to increased pulmonary vascular permeability, thrombotic disorders, severe
respiratory failure and higher mortality rates (Phase III) [2,14]. Inflammatory disorder and cytokine expression in
severe COVID-19 manifestation are comparable to that observed in ARDS [15]. CS influence different inflammatory
pathways, demonstrating to reduce mortality in patients with ARDS [16]. However, in order to be effective, CS
should be started early following the ARDS development [17].
 The RECOVERY trial has demonstrated that once-daily administration of 6 mg of dexamethasone was associated
with reduced mortality compared with patients treated with standard of care (29.3 vs 41.4% respectively) [18];
 In a retrospective analysis of 201 individuals with COVID-19 pneumonia, patients who developed. ARDS, had
lower mortality if methylprednisolone was added to the standard of care. Methylprednisolone at 1–2 mg/kg/d
was also associated with faster recover of Sp02 in 46 patients with mild COVID-19 manifestations [19];
 Early use of CS displayed reduced exposure to invasive mechanical ventilation, intensive care unit admission and
overall mortality in a multi-center study by Fadel et al. [20];
 Recently, a recent meta-analysis of seven randomized clinical trials evaluating the efficacy of CS in critically
ill patients with COVID-19, found reduced mortality among 678 individuals who received CS than in 1025
patients who were not (p < 0.01) [21]. The pooled analysis from this study has offered evidence that survival
rates have improved in critically ill patients with COVID-19 treated with CS [21]. Similar results were observed
even in our series of COVID-19 patients (data not yet published);
 Following the results from the RECOVERY trial and other evidence about the efficacy of CS in severe COVID-
19, including patients with ARDS, now recommendations from the main guidelines have been revised and now
CS are recommended for the treatment of patients with COVID-19 and severe or moderate manifestation by
requiring supplemental oxygen [18,22,23].
We believe that patient selection plays a pivotal role in the success of systemic CS administration. In fact, the very
early administration of systemic CS in patients with a stable mild disease, for example, without signs of respiratory
worsening or need for high-flow oxygen supply and constantly low-grade inflammation established by markers
such as C-reactive protein, D-dimer, TNF and, fibrinogen might favor the first viral phase, resulting in high viral
replication and eventually precipitating the subsequent phases. On the other hand, CS administration late in the
course of the inflammatory stage, once the immune system activation has been established, could be unhelpful
to prevent lung injuries. Thus, the effort should be directed to pinpoint the threshold at which a patient could
benefit from CS administration. Progressive respiratory illness in COVID-19 is associated with marked elevation
of inflammatory markers such as CRP, PCT, ferritin and D-dimer [18,24]. Persistent fever is a common clinical
sign of systemic inflammation and has been associated to the development of respiratory failure and ARDS in
COVID-19 [25]. Thus, based on these findings, we tried to identify simple and reliable markers helping to select
early in the course of COVID-19 those patients that could benefit from systemic CS administration (Table 1).
The goal of early CS treatment is to prevent lung damage induced by the cytokine storm associated with the
development of ARDS. The evidence of CS on ARDS, regardless of the underlying cause has been estimated by a
recent meta-analysis of Ye et al. [13].
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3 different inhaled formulations for the management
of asthma: a pMDI, a DPI and a solution for nebulised
therapy.
Pharmacokinetic profile
Drug deposition in the lungs depends on the
inhaler device: 15% of BUD reached the lung
with a pMDI compared with 32% with a DPI.
Limited systemic bioavailability after
inhalation (highly plasma protein binding,
extensive first-pass elimination of oral BUD)
High lipophilicity and prolonged nasal
residency time (18.4 ± 4 h)
Low pulmonary deposition of MFNS (2%)
Low systemic bioavailability (rapid hepatic)
clearance and high plasma protein binding
free fraction <1%)
At the lungs, ciclesonide is converted to an
active metabolite, des-CIC.
High lipophilicity and formation of local depot
prolong pulmonary duration of action (>24 h)
High pulmonary deposition of CIC (52%)
Low systemic bioavailability (rapid hepatic
clearance and high plasma protein binding
free fraction <1%)
Low oral bioavailability (CIC is not activated in
the oropharynx)
Dosing: 2 sprays (50 mcg) in each nostril once daily
(total daily dose of 200 mcg).
Indications: allergic rhinitis, asthma, nasal polyps
Pharmacokinetic profile




pMDI: Pressurised metered dose inhaler; BUD: budesonide; DPI: Dry powder inhaler; MFNS: Mometasone furoate nasal spray; Mcg: micrograms; 
des-CIC: Desisobutyryl-ciclesonide; CIC: Ciclesonide
Figure 1. Main characteristics of inhaled corticosteroids with effect against SARS-COV-2.
BUD: Budesonide; CIC: Ciclesonide; des-CIC: Desisobutyryl-ciclesonide; DPi: Dry powder inhaler; Mcg: Micrograms; MFNS: Mometasone
furoate nasal spray; pMDI: Pressurized metered dose inhaler.
Inhaled CS in COVID-19
Early in the pandemic, physicians were expected that people affected by asthma or structural lung diseases, such
as chronic obstructive pulmonary disease (COPD), would have been more susceptible than others to severe
manifestations. However, the prevalence of COPD in patients with COVID-19 is below 3% [2,26].
In patients with COPD innate and adaptive immune response to respiratory infections is impaired, and in vitro
data suggest that the production of inflammatory cytokines in response to infective agents could be reduced. Another
possibility is that some medications taken by patients with COPD might reduce the risk of infection. Inhaled CS
(ICS) with or without β2-agonist are the mainstay of treatment in asthma and COPD [27]. Ciclesonide (CIC) and
mometasone, two ICS used in asthma and allergic rhinitis have been found to significantly inhibit replication
of SARS-COV-2 and other coronaviruses in vitro. The association of immunomodulation and antiviral effect,
combined with the low rate of serious adverse events, could be useful for patients with COVID-19, presenting with
mild symptoms, to reduce the risk of progression to severe manifestations. Yamaya et al. found that glycopyrronium,
formoterol, and budesonide reduced the viral replication of HCoV-229E on airway epithelial cells [28].
Clinical data about the effectiveness of ICS in patients with COVID-19 is limited and anecdotical [29]. The efficacy
and safety of CIC and budesonide/formoterol in patients with mild COVID-19 are currently under investigation
in two RCT (ClinicalTrials.gov identifier: NCT04330586, NCT04377711, NCT04416399, NCT04355637,
NCT04331470 NCT04331054) and will contribute to elucidate the answer.
We report the features of the main inhaled CS with effect against SARS-CoV-2 (Figure 1). The role of ICS
against COVID-19 is still under investigation, but we should consider their potential because of their antiviral
Table 2. New parameters proposed to identify patients that may benefit from inhaled steroids in COVID-19.
Inclusion criteria Exclusion criteria
Hospitalized with ≥1: Patients taking chronic medications known to prolong QT interval
- No evidence of diffuse bilateral infiltrates on chest x-ray or CT scan O2 demand 5 l/min
- Cough or shortness of breath Contraindications/hypersensitivity to treatment with one or more agents.
- Sp02 94% in room air ICU admission
- Requiring O2 supply with nasal cannulas or facial mask (not exceeding 5 l/min)
ICU: Intensive care unit; O2: Oxygen; SpO2: Oxygen saturation.
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effect in vitro, particularly for molecules with the highest potential such as CIC and mometasone. Concerning to
the characteristics of ICS described above, the ideal timing of administration would be in an earlier stage compared
with systemic CS, in other words when SARS-CoV-2 is in the first replicative phase. Here we tried to elucidate the
characteristics of patients in the early replicative phase of COVID-19, that could benefit from ICS administration
(Table 2).
Future perspective
The emergence of SARS-CoV-2 infection requires urgently new therapeutic options. Currently, evidence on the
effectiveness of CS came from observational, retrospective series and a recent randomized controlled trial. Systemic
CS are undoubtedly molecules suffering some complications and their use should be evaluated carefully. CS could
help to reduce lung injuries in patients rapidly progressing to ARDS with signs of systemic inflammatory response
and requiring increasing demand for oxygen. Conversely, in the viral and early phase of infection, characterized by
mild respiratory symptoms, the use of systemic CS could precipitate hypoxemia and respiratory failure.
On the other hand, inhaled CS could find their rationale in the treatment of COVID-19 by the evidence that
SARS-CoV-2 replicates early in the upper respiratory tract including nasal epithelium, trachea, bronchi and only
subsequently in lungs [30]. Probably, CIC is a good candidate for its antiviral properties and for its restricted anti-
inflammatory activity to the desired site of action, since it is converted to its pharmacologically active metabolite at
the lungs. Considering also its low oral bioavailability, high hepatic clearance and plasma protein binding, systemic
exposure is very low, resulting in fewer side effects, such as adrenal suppression. The early administration of inhaled
CS with direct antiviral activity in addition to immunomodulatory effect might be considered in patients with
SARS-CoV-2 infection even without asthma or COPD presenting with COVID-19 pneumonia with mild oxygen
demand.
There is now strong evidence that CS are associated with improved survival among critically ill patients with
COVID-19 in both mechanically ventilated or receiving other types of oxygen supply. For the first time, based on
the current evidence available, we tried to elucidate simple criteria helping to identify the exact threshold at which
inhaled and systemic CS could be started in patients with COVID-19. Further studies and clinical trials exploring
the role of inhaled and systemic CS will definitively provide an answer to elucidate the timing of systemic CS
administration and the role of inhaled steroids in the treatment of COVID-19.
Executive summary
Background
• Glucocorticoids are hormones that regulate a wide range of physiologic activities and are essential for life. They
are widely used in medicine due to their profound immune-modulatory actions by decreasing the inflammatory
response.
Systemic corticosteroids
• Systemic corticosteroids (CS): efficacy and safety of CS in COVID-19 is based on previous experience with other
coronaviruses.
• CS have reduced the mortality of patients with COVID-19 and sever respiratory failure but the timing of
administration, is unclear.
• CS should be administered early at the onset of respiratory failure when inflammatory markers rapidly
deteriorate.
Inhaled CS
• Inhaled CS are the mainstay of the treatment of asthma while systemic CS are used for a variety of inflammatory
conditions.
• In vitro studies with budesonide, in combination with glycopyrronium and formoterol, demonstrated to inhibit
replication and cytokine production against some strains of coronavirus.
• Ciclesonide in vitro blocks SARS-CoV-2 ribonucleic acid replication and inhibits SARS-CoV-2 cytopathic activity.
• Patients with non-severe manifestation of COVID-19 might benefit from inhaled CS by directly reducing the viral
load and modulating the inflammation in the upper airways.
Future perspective
• CS have been shown to reduce mortality in SARS-CoV-2 infection and to reduce viral load in the first airways, in
vitro, however it will be essential to identify valid criteria to pinpoint the correct timing of administration and
therefore achieve the maximum benefit from the administration of these molecules.
10.2217/fmb-2020-0199 Future Microbiol. (Epub ahead of print) future science group
COVID-19 pneumonia: do not leave the corticosteroids behind! Special Report
Author contributions
S M Pinna and S Scabini conceived of the presented idea. SM Pinna developed the theory and performed the computations. S
Corcione and T Lupia aimed to the final revision of the manuscript. FGD Rosa supervised the findings of this work. All authors
discussed the results and contributed to the final manuscript.
Acknowledgments
The authors would like to thank Gloria Palazzo and Nour Shbaklo, who provided critical feedback and helped during the research.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or finan-
cial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria,
stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
References
Papers of special note have been highlighted as: • of interest
1. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180(7), 934–943 (2020).
2. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet 395(10229), 1054–1062 (2020).
3. Lee N, Allen Chan KC, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA
concentrations in adult patients. J. Clin. Virol. 31(4), 304–309 (2004).
4. Arabi YM, Mandourah Y, Al-Hameed F et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am.
J. Respir. Crit. Care Med. 197(6), 757–767 (2018).
5. Khalid I, Alraddadi BM, Dairi Y et al. Acute management and long-term survival among subjects with severe middle east respiratory
syndrome coronavirus pneumonia and ARDS. Respir. Care 61(3), 340–348 (2016).
6. Zhao Z, Zhang F, Xu M et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in
Guangzhou, PR China. J. Med. Microbiol. 52(8), 715–720 (2003).
7. Lee N, Allen Chan KC, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA
concentrations in adult patients. J. Clin. Virol. 31(4), 304–309 (2004).
8. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East Respiratory
Syndrome Coronavirus (MERS-CoV) infection: a cohort study. Travel Med. Infect. Dis. 29, 48–50 (2019).
9. Arabi YM, Arifi AA, Balkhy HH et al. Clinical course and outcomes of critically ill patients with middle east respiratory syndrome
coronavirus infection. Ann. Intern. Med. 160(6), 389–397 (2014).
10. Hsu L, Lee C, Green JA et al. Clinical features of index patient and initial contacts. Emerg. Infect. Dis. 9(6), 713–717 (2003).
11. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. (2020).
https://www.who.int/publications-detail/clinical-management-of -severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-in
fection-is-suspected
12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet
395(10223), 473–475 (2020).
13. Ye Z, Wang Y, Colunga-Lozano LE et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other
coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and
meta-analysis. CMAJ 192(27), E755–E767 (2020).
14. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart
Lung Transplant. 39(5), 405–407 (2020).
15. Azkur AK, Akdis M, Azkur D et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Allergy 75(7), 1564–1581 (2020).
16. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale
for prolonged glucocorticoid therapy. Chest 136(6), 1631–1643 (2009).
17. Steinberg KP, Hudson LD, Goodman RB et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
N. Engl. J. Med. 354(16), 1671–1684 (2006).
18. RECOVERY Collaborative Group, Horby P, Lim WS et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary
report. N. Engl. J. Med. doi:10.1056/NEJMoa2021436 (2020) (Epub ahead of print).
future science group 10.2217/fmb-2020-0199
Special Report Mornese Pinna, Scabini, Corcione, Lupia & De Rosa
• This is the first evidence from a randomized controlled trial that demonstrated an association between corticosteroids (CS) and
28-day all-cause mortality in critically ill patients with COVID-19-related acute respiratory distress syndrome.
19. Wang Y, Jiang W, He Q et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19
pneumonia: single-center experience from Wuhan, China. medRxiv 2020.03.06.20032342 (2020) (Epub ahead of print).
20. Fadel R, Morrison AR, Vahia A et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis.
https://doi.org/10.1093/cid/ciaa601 (2020) (Epub ahead of print).
• Highlights that in COVID-19, CS should be administrated early in patients with signs and symptoms of respiratory failure in
order to achieve the greatest benefit on clinical outcomes. In fact, the early CS administration in the ‘intervention group’ resulted
in a significant reduction in death rate and intensive care unit admission compared to the standard-of-care group in which CS
were used later.
21. Group TWHOREA for C-19 T (REACT) W. Association between administration of systemic corticosteroids and mortality among
critically Ill patients with COVID-19: a meta-analysis. JAMA 324(13), 1330–1341 (2020).
• This meta-analysis is based on data from seven RCTs of patients with a severe manifestation of COVID-19 and provides
sufficient evidence that CS improve overall survivals in critically ill patients with COVID-19 with the greatest effect in patients
not mechanically ventilated, suggesting that, when extensive lung injuries have already been established, the benefit from CS is
reduced.
22. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of
Health. http://www.covid19treatmentguidelines.nih.gov/
23. Adarsh Bhimraj A, Morgan RL, Hirsch Shumaker A et al. Infectious Diseases Society of America Guidelines on the treatment and
management of patients with COVID-19 (2020). http://www.idsociety.org/COVID19guidelines
24. Shang Y, Liu T, Wei Y et al. Scoring systems for predicting mortality for severe patients with COVID-19. EClinicalMedicine 24, 100426
(2020).
25. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180(7), 934–943 (2020).
26. Alqahtani JS, Oyelade T, Aldhahir AM et al. Prevalence, severity and mortality associated with COPD and smoking in patients with
COVID-19: a rapid systematic review and meta-analysis. PLoS ONE 15(5), e0233147 (2020).
27. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur. Respir.
J. 55(5), 2001009 (2020).
28. Yamaya M, Nishimura H, Deng X et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E
replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir. Investig. 58(3), 155–168
(2020).
29. Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. Therapeutic potential of ciclesonide inahalation for COVID-19
pneumonia: report of three cases. J. Infect. Chemother. 26(6), 625–632 (2020).
• Some inhaled steroids such as ciclesonide, have a potential role against SARS-CoV-2. After this case series, encouraged by the
results of Matsuyama et al. (The inhaled CS ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. BioRxiv
2020:2020.03.11.987016. https://doi.org/10.1101/2020.03.11.987016) in vitro, there are now ongoing studies exploring the
beneficial effects of inhaled CS in COVID-19.
30. Rockx B, Kuiken T, Herfst S et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science
368(6494), 1012–1015 (2020).
10.2217/fmb-2020-0199 Future Microbiol. (Epub ahead of print) future science group
